Although some of the studies found that miR-135 acts as an antioncogene in several cancers including OS (40), and this is the first report that miR-135a can inhibit OS development by targeting BMI1 and KLF4 in vitro and in vivo. This evidence concerns the gene KLF4 and cancer.